The drugmaker attributed its decision to file for bankruptcy protection to increased generic competition and losing two key products. It also has struggled with debt.
Pernix has entered into an asset purchase agreement with debt holder Highbridge Capital Management. The agreement serves as a stalking-horse bid to acquire most of the drugmaker’s assets for about $76 million.
The company plans to continue operations while working to complete the sale of its assets.
More articles on pharmacy:
23andMe wants to become a drug company, has 13 drugs in its pipeline: 5 notes
J&J CEO on partnership with Apple: ‘We’re going to save lives’
Medicare would pay for CAR-T therapy under new proposal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
